Dario Renato Alessi (born 1967) is a French-born British biochemist, Director of the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) and Professor of Signal Transduction, at the School of Life Sciences, University of Dundee.[2][3][4][5][6]
Dario Alessi | |
|---|---|
| Born | Dario Renato Alessi December 1967 (age 56)[1] France |
| Nationality | British |
| Alma mater | University of Birmingham |
| Known for | Protein kinase research |
| Awards |
|
| Scientific career | |
| Fields | protein phosphorylation |
| Institutions | University of Dundee |
| Doctoral advisor | Philip Cohen (postdoc) |
| Website | lifesci |
Education and career
editHe attended high school in Brussels. He graduated from the University of Birmingham, with a Bachelor of Science in biochemistry in 1988, and with a PhD in 1991, where he studied with Ian Trayer and David Trentham.[7] His postdoctoral research was with Sir Philip Cohen FRS at the University of Dundee from 1991 to 1997. He became Professor of Signal Transduction at the University of Dundee in 2003 and Director of the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) in 2012.[8][9]
Research
editAlessi's work is concerned with unravelling the roles of poorly characterised components that regulate protein phosphorylation or ubiquitylation that have emerged from the genetic analysis of human disease. The aim of his research is to provide new knowledge to enable researchers to devise improved strategies for the treatment of Parkinson's disease.[10] In particular, Dario's research focusses on the leucine-rich repeat kinase LRRK2, as mutations that increase the kinase activity of this protein are one of the most common causes of inherited Parkinson's disease.[2] Dario Alessi is also the current Director of the Division of Signal Transduction Therapy Unit (DSTT) which is a unique collaboration between University of Dundee and six major pharmaceutical companies (AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline GlaxoSmithKline, Merck KGaA, Janssen Pharmaceuticals and Pfizer) that aims to accelerate drug discovery in the areas of protein phosphorylation and ubiquitylation.[11] As of 2013 he has written over 180 peer-reviewed papers and has been cited more than 32,000 times, making him one of the most highly cited biochemists in the world.[12]
Honours and awards
editAlessi has received many awards, among these the Colworth Medal (1999), the Eppendorf Young European Investigator Award (2000), Philip Leverhulme Prize (2002), EMBO Gold Medal (2005) and the Francis Crick Prize Lecture of the Royal Society (2006). He was elected a Fellow of the Royal Society of Edinburgh in 2002, Member of the European Molecular Biology Organisation (EMBO) in 2005, Fellow of the Royal Society in 2008 and Fellow of the Academy of Medical Sciences (FMedSci) in 2012.[13] In 2023 he was awarded the Louis-Jeantet Prize for Medicine.[14] [15]
Alessi was appointed Officer of the Order of the British Empire (OBE) in the 2023 Birthday Honours for services to biomedical research and translation.[16]
References
edit- ^ "ALESSI, Prof. Dario Renato". Who's Who. Vol. 2014 (online Oxford University Press ed.). A & C Black. (Subscription or UK public library membership required.)
- ^ a b "Dario Alessi | College of Life Sciences". Retrieved 13 November 2011.
- ^ "MRC Protein Phosphorylation Unit :: Research :: Dario Alessi". Retrieved 13 November 2011.
- ^ "Dario Alessi – SCILLS – The Scottish Institute for Cell Signalling". Archived from the original on 19 February 2012. Retrieved 13 November 2011.
- ^ "* Dario Alessi (professor), Scotland – Online Encyclopedia of the Italian Scientists and Scholars in America". Archived from the original on 20 October 2014. Retrieved 13 November 2011.
- ^ Cross, D. A.; Alessi, D. R.; Cohen, P; Andjelkovich, M; Hemmings, B. A. (1995). "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B". Nature. 378 (6559): 785–9. Bibcode:1995Natur.378..785C. doi:10.1038/378785a0. PMID 8524413. S2CID 4285651.
- ^ Alessi, D. R.; Corrie, J. E.; Fajer, P. G.; Ferenczi, M. A.; Thomas, D. D.; Trayer, I. P.; Trentham, D. R. (1992). "Synthesis and properties of a conformationally restricted spin-labeled analog of ATP and its interaction with myosin and skeletal muscle". Biochemistry. 31 (34): 8043–8054. doi:10.1021/bi00149a039. PMID 1324724.
- ^ Gong, M. C.; Fuglsang, A.; Alessi, D.; Kobayashi, S.; Cohen, P.; Somlyo, A. V.; Somlyo, A. P. (1992). "Arachidonic acid inhibits myosin light chain phosphatase and sensitizes smooth muscle to calcium". The Journal of Biological Chemistry. 267 (30): 21492–21498. doi:10.1016/S0021-9258(19)36636-0. PMID 1328235.
- ^ "MRC Clinical Sciences Centre – Overview – Scientific Advisory Board – Dario Alessi". Archived from the original on 25 April 2012. Retrieved 13 November 2011.
- ^ "Dario Alessi's research page". Retrieved 22 November 2013.
- ^ "Division of Signal Transduction Therapy Unit". Archived from the original on 5 December 2013. Retrieved 22 November 2013.
- ^ "ISI". Archived from the original on 4 May 2013. Retrieved 22 November 2013.
- ^ "Dario Alessi: MRC PPU – Awards". Retrieved 22 November 2013.
- ^ Louis-Jeantet Prize 2023
- ^ "£440,000 prize for Dundee researcher". 23 January 2023.
- ^ "No. 64082". The London Gazette (Supplement). 17 June 2023. p. B11.